The COVID-19 pandemic demonstrated that the biopharmaceutical manufacturing industry can continue to benefit from more advances to help improve and accelerate vaccine manufacturing processes to bolster the nation’s pandemic response capability.
MIT will demonstrate the rapid production of virus-like particle (VLP) vaccine candidates manufactured using a transposon-based system. This process involves co-transfection to yield polyclonal cell lines that secrete self-assembling SARS-CoV-2 VLPs containing the four viral structural proteins.
The team’s expertise in synthetic biology, biological process modeling and control, machine learning, and manufacturing process development can help shorten timelines for process development and scale-up.
The MIT team aims to improve product development of VLPs, mechanistic modeling for rapid-cycle process development and improved process control.
By demonstrating this transposon-based system, the team will provide industry with tools and approaches to rapidly develop and manufacture effective virus-like particle vaccines, adding robustness to the nation’s pandemic response to emerging viruses.
This project will provide industry with tools and approaches to rapidly develop and manufacture effective virus-like particle vaccines, which will add robustness to the nation’s pandemic response to emerging viruses.
Establish a lentiviral cassette system for VLP generation for two candidate vaccines and demonstrate manufacturability at a small scale in micro-bioreactors Establish mechanistic models describing the VLP production process Demonstration of scaled-up perfusion process for production of VLP vaccines
Andrew Kane1, Charles Swofford2, Christopher Canova3, Hayden Sandt1, Zeyu Yang2, Nevin Summers1, Flora Keumurian2, Jacqueline Wolfrum2, Richard Braatz3, Anthony Sinskey4, Ron Weiss1, Stacy Springs2 1Department of Biological Engineering2Center for Biomedical Innovation3Department of Chemical Engineering4Department of BiologyMassachusetts Institute of Technology, Cambridge, MA, USA
Christopher Canova1, Andrew Kane2, Charles Swofford3, Pavan Inguva1, Hayden Sandt2, Flora Keumurian3, Nevin Summers2, Jacqueline Wolfrum3, Richard Braatz1, Anthony Sinskey4, Ron Weiss2, Stacy Springs3 1Department of Chemical Engineering 2Department of Biological Engineering3Center for Biomedical Innovation4Department of BiologyMassachusetts Institute of Technology, Cambridge, MA, USA
Christopher T. Canova, Pavan K. Inguva, Richard D. BraatzDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
Swofford, C., Presenter, ARP-14: Accelerating the manufacture and scale up of virus-like particle vaccines, NIIMBL National Meeting, Washington, D.C., July 28, 2022.
Christopher Canova1, Andrew Kane2, Charles Swofford3, Pavan Inguva1, Hayden Sandt2, Flora Keumurian3, Nevin Summers2, Jacqueline Wolfrum3, Richard Braatz1, Anthony Sinskey4, Ron Weiss2, Stacy Springs3 1Department of Chemical Engineering 2Department of Biological Engineering3Center for Biomedical Innovation4Department of BiologyMassachusetts Institute of Technology, Cambridge, MA, USA
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Massachusetts Institute of Technology
